Segment Reporting - Summary of Segment Loss (Details) - USD ($) $ in Thousands	3 Months Ended						9 Months Ended
	Sep. 30, 2025	Jun. 30, 2025	Mar. 31, 2025	Sep. 30, 2024	Jun. 30, 2024	Mar. 31, 2024	Sep. 30, 2025	Sep. 30, 2024
Segment Reporting [Abstract]
CDMO, CRO and Other Third-party Preclinical Studies, Clinical Trials and Consulting Costs	$ 7,437			$ 3,170			$ 19,164	$ 7,044
License fees, milestone payments, and annual maintenance fees related to acquired technologies	7			32,144			7	32,194
Internal research and development personnel expenses	1,455			597			3,699	1,615
Other research and development costs	227			109			726	339
General and administrative personnel expenses	1,137			580			2,908	1,348
Other general and administrative expenses	2,478			1,249			8,847	2,059
Interest expense				815			1,443	1,392
Other segment items	(847)			(580)			(3,354)	1,150
Net loss	$ (11,894)	$ (11,350)	$ (10,196)	$ (38,084)	$ (5,650)	$ (3,407)	$ (33,440)	$ (47,141)